Therapeutic and adverse actions of serotonin transporter substrates

Pharmacology and Therapeutics

Volumn 95, Issue 1, 2002, Pages 73-88

  Rothman, Richard B ^a   Baumann, Michael H ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Fenfluramine; Neurotoxicity; Primary pulmonary hypertension; Serotonin transporter; Valvular heart disease

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1 (3 TRIFLUOROMETHYLPHENYL)PIPERAZINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMINOREX; AMPHETAMINE; CHLORPHENTERMINE; DESIPRAMINE; DEXFENFLURAMINE; FENFLURAMINE; FLUOXETINE; METHAMPHETAMINE; NORADRENALIN; NORFENFLURAMINE; PHENTERMINE; RECEPTOR SUBTYPE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; ANOREXIGENIC AGENT; SEROTONIN RECEPTOR AFFECTING AGENT;

AFFECTIVE NEUROSIS; ALCOHOL CONSUMPTION; ANOREXIA; ANXIETY NEUROSIS; BULIMIA; CLINICAL TRIAL; DEPRESSION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; HUMAN; IC 50; NEUROTOXICITY; NONHUMAN; NORADRENALIN RELEASE; OBESITY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; SEROTONIN RELEASE; STEREOCHEMISTRY; STEREOISOMERISM; SUBSTANCE ABUSE; VALVULAR HEART DISEASE; ANIMAL; BRAIN; CHEMICALLY INDUCED DISORDER; CYTOLOGY; METABOLISM; SYNAPTOSOME;

ANIMAL; APPETITE DEPRESSANTS; BRAIN; HEART VALVE DISEASES; HUMAN; HYPERTENSION, PULMONARY; RECEPTORS, SEROTONIN; SEROTONIN AGENTS; SYNAPTOSOMES; ANIMALS; HUMANS;

EID: 0035993478     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00234-6     Document Type: Review

References (182)

1. Appetite-suppressant drugs and the risk of pulmonary hypertension
2. Differential effects of clomipramine given locally or systemically on extracellular 5-hydroxytryptamine in raphe nuclei and frontal cortex. An in vivo brain microdialysis study
3. Neurotransmitter transporters: Recent progress
4. Neurotransmitter transporters as molecular targets for addictive drugs
5. Haemodynamic, metabolic and endocrine effects of short-term dexfenfluramine treatment in young, obese women
6. TFMPP and RU24969 enhance serotonin release from rat hippocampus
7. Primaere pulmonale hypertonie
8. 3,4-Methylenedioxymethamphetamine (MDMA) as a unique model of serotonin receptor function and serotonin-dopamine interactions
9. Cardiovascular safety of second-generation antihistamines
10. Single and multiple dose pharmacokinetics of nefazodone in subjects classified as extensive and poor metabolizers of dextromethorphan
11. 3H]paroxetine-labeled serotonin uptake sites
12. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
13. Neuroendocrine responsiveness to serotonergic drug challenge during cocaine withdrawal
14. Combined phentermine/fenfluramine administration and central serotonin neurons
15. Intravenous administration of the serotonin agonist m-chlorophenylpiperazine (mCPP) increases extracellular serotonin in the diencephalon of awake rats
16. Effects of d-fenfluramine and m-chlorophenylpiperazine on acute 5-HT release and long-term 5-HT depletion in rat brain
17. The serotonin agonist m-chlorophenylpiperazine (mCPP) binds to serotonin transporter sites in human brain
18. Functional consequences of central serotonin depletion produced by repeated fenfluramine administration in rats
19. Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: Therapeutic implications
20. 1-(m-Chlorophenyl)piperazine (mCPP) dissociates in vivo serotonin release from long-term serotonin depletion in rat brain
21. Fenfluramine-induced pulmonary vasoconstriction: Role of serotonin receptors and potassium channels
22. The substituted amphetamines 3,4-methylenedioxymethamphetamine, methamphetamine, p-chloroamphetamine and fenfluramine induce 5-hydroxytryptamine release via a common mechanism blocked by fluoxetine and cocaine
23. Molecular physiology of norepinephrine and serotonin transporters
24. Treatment of bulimia with fenfluramine and desipramine
25. D-Fenfluramine suppresses the increased calorie and carbohydrate intakes and improves the mood of women with premenstrual depression
26. Dissociation of serotonergic regulation of anxiety and ethanol self-administration: A study with mCPP
27. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs
28. Agony and ecstasy: A review of MDMA effects and toxicity
29. Craving for cocaine in addicted users. Role of serotonergic mechanisms
30. Effect of fenfluramine challenge on cocaine craving in addicted male users
31. Pharmacokinetics of fenfluramine and norfenfluramine in volunteers given D- and DL-fenfluramine for 15 days
32. Involvement of free radicals in MDMA-induced neurotoxicity in mice
33. Factors that may effect the reduction of hunger and body weight following d-fenfluramine administration
34. Effects of chronic treatment with dexfenfluramine on serotonin in rat blood, brain and lung tissue
35. Cloning and expression of the mouse serotonin transporter
36. Quantitation of dexfenfluramine/D-norfenfluramine concentration in primate brain using F-19 NMR-spectroscopy
37. Measurement of human brain dexfenfluramine concentration by 19F magnetic resonance spectroscopy
38. Obesity drugs and the heart
39. Valvular heart disease associated with fenfluramine-phentermine
40. Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential
41. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine
42. Characterization of D-fenfluramine-induced hypothermia: Evidence for multiple sites of action
43. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability
44. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity
45. Non-linear pharmacokinetics of MDMA ('ecstasy') in humans
46. 2 receptor agonists in a conditioned taste aversion paradigm in the rat
47. Fenfluramine and dextroamphetamine treatment of childhood hyperactivity. Clinical and biochemical findings
48. Multiple serotonin receptors: Opportunities for new treatments for obesity?
49. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension
50. Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain
51. 3,4-Methylenedioxymethamphetamine induces monoamine release, but not toxicity, when administered centrally at a concentration occurring following a peripherally injected neurotoxic dose
52. 2C receptor-mediated phosphoinositide turnover and the stimulus effects of m-chlorophenylpiperazine
53. Aminorex to fen/phen: An epidemic foretold
54. Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices
55. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine
56. Stereochemistry of the metabolism of MDMA to MDA
57. Blood pressure and plasma norepinephrine responses to dexfenfluramine in obese postmenopausal women
58. Regional extracellular norepinephrine responses to amphetamine and cocaine and effects of clonidine pretreatment
59. Pharmacology of para-chloroamphetamine and analogs
60. Structure-activity relationships among the halogenated amphetamines
61. Pharmacologic properties of serotonergic agents and antidepressant drugs
62. Reversible and irreversible phases of serotonin depletion by 4-chloroamphetamine
63. Biological actions of drugs affecting serotonin and eating
64. Neurochemical mechanism of action of drugs which modify feeding via the serotoninergic system
65. 8-OH-DPAT attenuates the dexfenfluramine-induced increase in extracellular serotonin: An in vivo dialysis study
66. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine
67. SSRIs and SMRIs: Broad spectrum of efficacy beyond major depression
68. Effect of ascorbate and cysteine on the 3,4-methylenedioxymethamphetamine-induced depletion of brain serotonin
69. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions
70. In vivo criteria to differentiate monoamine reuptake inhibitors from releasing agents: Sibutramine is a reuptake inhibitor
71. Aminorex and pulmonary hypertension
72. Aminorex pulmonary hypertension
73. Differential effects of monoaminergic agonists on alcohol intake in rats fed a tryptophan-enhanced diet
74. Effects of phentermine and fenfluramine on alcohol consumption and alcohol withdrawal seizures in rats
75. Neuroendocrine effects of d-fenfluramine and bromocriptine following repeated smoked cocaine in humans
76. A comparison of sibutramine and dexfenfluramine in the treatment of obesity
77. The human serotonin transporter gene polymorphism - Basic research and clinical implications
78. Increased plasma serotonin in primary pulmonary hypertension
79. 3 receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats
80. Novel in vivo electrophysiological assay for the effects of cocaine and putative "cocaine antagonists" on dopamine transporter activity of substantia nigra and ventral tegmental area dopamine neurons
81. The effects of drugs used to treat obesity on the autonomic nervous system
82. Combined serotonin and dopamine indirect agonists correct alcohol craving and alcohol-associated neurosis
83. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin)
84. Efflux studies allow further characterisation of the noradrenaline and 5-hydroxytryptamine transporters in rat lungs
85. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation
86. Comparative serotonin neurotoxicity of the stereoisomers of fenfluramine and norfenfluramine
87. 3H]monoamine releasing and uptake inhibition properties of 3,4-methylenedioxymethamphetamine and p-chloroamphetamine analogues
88. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: Similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)
89. Presynaptic modulation of the release of dopamine from the rabbit caudate nucleus: Differences between electrical stimulation, amphetamine and tyramine
90. D-, L- and DL-fenfluramine cause long-lasting depletions of serotonin in rat brain
91. Effect of dexfenfluramine treatment on body weight, blood pressure and noradrenergic activity in obese hypertensive patients
92. Apomorphine does not alter amphetamine-induced dopamine release measured in striatal dialysates
93. Ethanol consumption following acute fenfluramine, fluoxetine, and dietary tryptophan
94. BMPR2 haploinsufficiency as the inherited molecular mechanism for primary pulmonary hypertension
95. Pulmonary hypertension, anorexigens and 5-HT: Pharmacological synergism in action?
96. Allometric issues in drug development
97. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat
98. The effect of selective serotonin releasing agents in the chronic mild stress model of depression in rats
99. Simultaneous effects of p-chloroamphetamine, d-fenfluramine, and reserpine on free and stored 5-hydroxytryptamine in brain and blood
100. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4-methylenedioxymethamphetamine in humans
101. Neurotransmitter transporters in the central nervous system
102. 2-adrenoceptors in the locus coeruleus are involved in the in vivo modulation of cortical noradrenaline release by the antidepressant desipramine
103. Brain serotonin neurotoxicity and primary pulmonary hypertension from fenfluramine and dexfenfluramine. A systematic review of the literature
104. Brain serotonin neurotoxicity and fenfluramine and dexfenfluramine [reply]
105. (+/-)3,4-Methylenedioxymethamphetamine ('ecstasy')-induced serotonin neurotoxicity: Clinical studies
106. Dexfenfluramine. A review of its pharmacological properties and therapeutic potential in obesity
107. In vitro and in vivo effects of the anorectic agent dexfenfluramine on the central serotoninergic neuronal systems of non-human primates. A comparison with the rat
108. Anorectic drugs and pulmonary hypertension from the bedside to the bench
109. Novel synergistic treatment of ethanol withdrawal seizures in rats with dopamine and serotonin agonists
110. Neurotoxicity of MDMA and related compounds: Anatomic studies
111. Effects of dopamine and serotonin-releasing agents on methamphetamine discrimination and self-administration in rats
112. Effect of the R(-) and S(+) isomers of MDA and MDMA on phosphatidyl inositol turnover in cultured cells expressing 5-HT2A or 5-HT2C receptors
113. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA)
114. Comparative haemodynamic effects of clonidine and guanfacine
115. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
116. Treatment of seasonal depression with d-fenfluramine
117. Correlation between steady-state plasma concentrations of mianserin and trazodone in depressed patients
118. Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites
119. Conclusive evidence for distinct transporters for 5-hydroxytryptamine and noradrenaline in pulmonary endothelial cells of the rat
120. The addition of dexfenfluramine to fluoxetine in the treatment of obesity: A randomized clinical trial
121. Serotonin-releasing effects of substituted piperazines in vitro
122. Fenfluramine: A review of its pharmacological properties and therapeutic efficacy in obesity
123. Autoregulation of serotonin neurons: Role in antidepressant drug action
124. 2C receptors in CHO-K1 cells
125. Fenfluramine augmentation in tricyclic-refractory depression
126. SSRI treatment decreases prolactin and hyperthermic responses to mCPP
127. Linking a serotonin transporter polymorphism to vascular smoothmuscle proliferation in patients with primary pulmonary hypertension
128. Effects of chronic fenfluramine on blood serotonin, cerebrospinal fluid metabolites and behavior in monkeys
129. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization
130. Valvular heart disease associated with fenfluramine-phentermine
131. Pharmacologic induction of weight loss to treat type 2 diabetes
132. Anorexigens and pulmonary hypertension in the United States: Results from the surveillance of North American pulmonary hypertension
133. Emotional symptomatology in obese patients treated with fenfluramine and dextroamphetamine
134. Suppression of eating by fenfluramine in patients with bulimia nervosa
135. Treatment of alcohol and cocaine addiction by the combination of pemoline and fenfluramine: A preliminary case series
136. Neurochemical mechanisms of phentermine and fenfluramine: Therapeutic and adverse effects
137. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates: Implications for primary pulmonary hypertension
138. 2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications
139. Neurochemical neutralization of methamphetamine with high affinity non-selective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
140. Chronic treatment with the phentermine combined with fenfluramine lowers plasma serotonin
141. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin
142. Primary pulmonary hypertension
143. Mechanisms of biogenic amine transporters
144. From synapse to vesicle: The reuptake and storage of biogenic amine neurotransmitters
145. Systemic uptake inhibition decreases serotonin release via somatodendritic autoreceptor activation
146. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA ("ectasy")-induced degeneration of 5-HT nerve endings in rat brain
147. Antiobesity pharmacotherapy in the management of type 2 diabetes
148. In-vivo detection of short-term and long-term MDMA neurotoxicity - A positron-emission-tomography study in the living baboon brain
149. Drug-induced primary vascular pulmonary hypertension. Contribution to its etiology and clinical course. (German)
150. 1B receptor ligands exist?
151. Guanfacine in essential hypertension: Effect on blood pressure, plasma noradrenaline concentration and plasma renin activity
152. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters
153. Effects of 5-HT-releasing agents on the extracellullar hippocampal 5-HT of rats. Implications for the development of novel antidepressants with a short onset of action
154. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction
155. Effect of 3,4-methylenedioxymethamphetamine (MDMA) on hippocampal dopamine and serotonin
156. Involvement of the serotonin transporter in the formation of hydroxyl radicals induced by 3,4-methylenedioxymethamphetamine
157. Ascorbic acid prevents 3,4-methylenedioxymethamphetamine (MDMA)-induced hydroxyl radical formation and the behavioral and neurochemical consequences of the depletion of brain 5-HT
158. The effects of fenfluramine (hydrochloride) on the behaviors of fifteen autistic children
159. Electrophysiological effects of fluoxetine and duloxetine in the dorsal raphe nucleus and hippocampus
160. Immunohistochemical study of short- and long-term effects of DL-fenfluramine on the serotonergic innervation of the rat hippocampal formation
161. An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine
162. Serotonin: It's possible to have too much of a good thing
163. Effects of fenfluramine on eight outpatients with the syndrome of autism
164. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-β family
165. Neurotransmitter transporters: Three important gene families for neuronal function
166. Reduced satiating effect of d-fenfluramine in serotonin 5-HT(2C) receptor mutant mice
167. Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers
168. Further studies to examine the nature of dexfenfluramine-induced suppression of heroin self-administration
169. A comparison of the acute effects of dextroamphetamine and fenfluramine in depression
170. Drug treatment of obesity
171. A double-blind clinical trial in weight control. Use of fenfluramine and phentermine alone and in combination
172. Anorexic agents aminorex, fenfluramine, and dexfenfluramine inhibit potassium current in rat pulmonary vascular smooth muscle and cause pulmonary vasoconstriction
173. Appetite suppressants and valvular heart disease
174. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo
175. The effects of dexfenfluramine on blood glucose control in patients with type 2 diabetes
176. Obese patients with type 2 diabetes poorly controlled by insulin and metformin: Effects of adjunctive dexfenfluramine therapy on glycaemic control
177. An investigation into the effects of 5-HT agonists and receptor antagonists on ethanol self-administration in the rat
178. Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders
179. Amphetamine and fenfluramine suppress ethanol intake in ethanol-dependent rats
180. Effects of repeated fenfluramine administration on indices of monoamine function in rat brain: Pharmacokinetic, dose response, regional specificity and time course data
181. The effects of aminorex and related compounds on brain monoamines and metabolites in CBA mice
182. Anxiety disorders: A review of tricyclic antidepressants and selective serotonin reuptake inhibitors